Price Disclosure Reductions for 2022 October Cycle
Page last updated: 18 November 2022
The 2022 October cycle has a data collection period of 1 October 2021 to 31 March 2022.
Responsible persons must have disclosed brand data to the Price Disclosure Data Administrator (PDDA) by the deadline of 12 May 2022.
The reduction day is 1 October 2022.
Responsible persons should ensure that their authorised representatives keep their details up to date via the Health Products Portal, and sign up to the PBS Newsletter.
- Outcomes of Price Disclosure calculations
- Indicative prices of brands scheduled for a price disclosure reduction
- Confirmed prices of brands scheduled for a price disclosure reduction
- Brand price reductions and savings to patients
Outcomes of Price Disclosure calculations
The PDDA calculates weighted average disclosed prices (WADPs) to be provided to the Department of Health. The Minister determines WADPs calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).
The outcomes reflecting these determinations can now be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2022 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 31 March 2022 will also take the reduction on 1 October 2022 under section 99ADHA of the Act.
Please note an agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes was by 5:00pm AEST on 8 July 2022.
A list of pharmaceutical items scheduled for a price disclosure reduction and their weighted average disclosed prices is available in the 2022 October Cycle Outcomes Summary (Excel 32KB).
A list of brands of pharmaceutical items that are subject to an automatic flow-on price disclosure reduction under section 99ADHB of the National Health Act 1953 on 1 October 2022 is available in the 2022 October Combination Flow-on Reductions from Price Disclosure Summary (Excel 16 KB)
Indicative prices of brands scheduled for a price disclosure reduction
The dispensed prices for brands scheduled for price disclosure reductions in this cycle will be published to assist responsible persons and other stakeholders.
Indicative prices are not published for any medicines that are:
- not taking a price disclosure reduction in this cycle;
- new brands after the date of publication;
- brands with other price changes on the reduction day.
The indicative prices reports have been replaced by confirmed prices reports which are available below.
Confirmed prices of brands scheduled for a price disclosure reduction
This report sets out the dispensed prices of brands scheduled for a price disclosure reduction.
The confirmed prices reports are available below.
- 2022 October Cycle Confirmed Prices Report (excluding EFC drugs) (Excel 226 KB) - (PDF 3.43 MB)
- 2022 October Cycle Confirmed Prices Report (EFC drugs only) (Excel 26 KB) - (PDF 362 KB)
Brand price reductions and savings to patients
This report sets out price reductions per brand and potential individual savings to non-concessional patients from 1 October 2022. This information is made available to assist patients with understanding how much they may save on their PBS medicines.
The report does not include any brands of medicines that have other price changes, or brands that are new to the PBS on the reduction day. Some of the savings in the report may change as a result of outcomes from the Price Disclosure Dispute Resolution Process.
The brand price reduction report is available below: